If you have been looking for Mutual Fund Equity Report funds, a place to start could be Fidelity Advisor Biotechnology I (
FBTIX Quick Quote FBTIX - Free Report) . FBTIX holds a Zacks Mutual Fund Rank of 2 (Buy), which is based on nine forecasting factors like size, cost, and past performance. History of Fund/Manager
Fidelity is based in Boston, MA, and is the manager of FBTIX. Fidelity Advisor Biotechnology I made its debut in December of 2000, and since then, FBTIX has accumulated about $1.04 billion in assets, per the most up-to-date date available. The fund's current manager, Eirene Kontopoulos, has been in charge of the fund since July of 2018.
Obviously, what investors are looking for in these funds is strong performance relative to their peers. This fund carries a 5-year annualized total return of 12.77%, and it sits in the top third among its category peers. Investors who prefer analyzing shorter time frames should look at its 3-year annualized total return of 12.7%, which places it in the top third during this time-frame.
When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. Compared to the category average of 15.99%, the standard deviation of FBTIX over the past three years is 21.33%. Over the past 5 years, the standard deviation of the fund is 20.84% compared to the category average of 13.46%. This makes the fund more volatile than its peers over the past half-decade.
Investors should note that the fund has a 5-year beta of 0.87, which means it is hypothetically less volatile than the market at large. Because alpha represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which is the S&P 500 in this case, one should pay attention to this metric as well. With a negative alpha of -1.3, managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns.
Costs are increasingly important for mutual fund investing, and particularly as competition heats up in this market. And all things being equal, a lower cost product will outperform its otherwise identical counterpart, so taking a closer look at these metrics is key for investors. In terms of fees, FBTIX is a no load fund. It has an expense ratio of 0.74% compared to the category average of 1.33%. So, FBTIX is actually cheaper than its peers from a cost perspective.
Investors should also note that the minimum initial investment for the product is $0 and that each subsequent investment has no minimum amount.
Overall, Fidelity Advisor Biotechnology I ( FBTIX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively strong performance, worse downside risk, and lower fees, this fund looks like a good potential choice for investors right now.
This could just be the start of your research on FBTIXin the Mutual Fund Equity Report category. Consider going to
www.zacks.com/funds/mutual-funds for additional information about this fund, and all the others that we rank as well for additional information. Zacks provides a full suite of tools to help you analyze your portfolio - both funds and stocks - in the most efficient way possible.